1 / 18

Carcinoma mammario metastatico CASO CLINICO n.2

Carcinoma mammario metastatico CASO CLINICO n.2. Stefania Gori Oncologia Medica- Perugia. Caso clinico n.2. Agosto 2009: Donna di anni 37 anni, premenopausa, operata altrove di quadrantectomia mammaria Sx + dissezione ascellare per ca. duttale infiltrante

moses-carter
Télécharger la présentation

Carcinoma mammario metastatico CASO CLINICO n.2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Carcinoma mammario metastaticoCASO CLINICO n.2 Stefania Gori Oncologia Medica- Perugia

  2. Caso clinico n.2 Agosto 2009: Donna di anni 37 anni, premenopausa, operata altrove di quadrantectomia mammaria Sx + dissezione ascellare per ca. duttale infiltrante pT2 pN3(20LN+/24) M0; STADIO IIIC • G3 • ER=0%, PgR=0% • Ki67=60% • HER2= 3+ IHC Settembre 2001: Programma terapeutico (altrove): CT adiuvante (FECTaxano) seguita da RT Aveva ricevuto 1° ciclo di F600E90C600

  3. Caso clinico n.2 Vengono richiesti: RM encefalo con gadolinio: negativa PET /TC total body (9 ottobre 2009): metastasi LN mediastinici metastasi ossee: - sterno e collo femore dx IV STADIO

  4. Trattamenti Ottobre 2009 IV stadio RT femore dx + Zometa Trastuzumab Paclitaxel Febbraio 2010 RC Zometa+ trastuzumab

  5. Trattamenti Ottobre 2009 IV stadio RT femore dx + Zometa Trastuzumab Paclitaxel Febbraio 2010 RC Zometa+ trastuzumab Nov 2010 PD SNC LN Osso

  6. Novembre 2010:RM encefalo T1 con gadolinio

  7. 1- Metastasi cerebrali di 6 e 13 mm di diametro (centro semiovale e corteccia frontale dx) asintomatiche, in pt con progressione extracranica asintomatica (ossea e linfonodale).Quale sequenza di trattamento? A- Trattamento locale terapia sistemica B- Terapia sistemica  trattamento locale

  8. Dicembre 2010 RT stereotassica su entrambe le lesioni (dose di riferimento:18 Gy)

  9. Systemic therapy in brain metastases from HER2+ BC: when? Extracranial disease and .. 1-3 brain lesions Multiple (>3) brain lesions Local treatment WBRT Systemic therapy Systemic therapy Systemic therapy WBRT The choice of systemic therapy must be tailored on the following factors: Performance Status and previous agents received

  10. Lapatinib+Capecitabine (all pts pretreated with CT) RETROSPECTIVE STUDIES PHASE II PROSPECTIVE STUDIES * Optional extension phase after cerebral progression

  11. Brain metastases in HER2+ breast cancer Causesofdeath

  12. Systemic therapy in brain metastases from HER2+ BC: when? Extracranial disease and .. 1-3 brain lesions Multiple (>3) brain lesions Local treatment WBRT Systemic therapy Systemic therapy Systemic therapy WBRT The choice of systemic therapy must be tailored on the following factors: Performance Status and previous agents received

  13. 2- Quale terapia sistemica? A- Trastuzumab-based therapy B- Lapatinib +capecitabine C- Chemotherapy only

  14. Brain metastases in HER2-positive Trastuzumab-pretreated MBC SYSTEMIC THERAPY OPTIONS- Sept 2011 • Trastuzumab-based therapy (?) retrospective data Newly diagnosed brain metastasesand no PD at extracranial sites • Lapatinib + capecitabine phase II trial- Bachelot ASCO 20111 retrospective study 2 Newly diagnosed brain metastases and PD at extracranial sites • Lapatinib + capecitabine phase II trial- Bachelot ASCO 20111 retrospective study 2 • Lapatinib + capecitabine • phase II trials 3,4; retrospective studies Brain progression after RT 1.Bachelot T, ASCO 2011 #505; 2.Metro G, Gori S, Ann Oncol 2011; 3.Lin NU, Clin Cancer Res 2009;4.Lin NU, J Neurooncol 2011 online

  15. Trattamenti Dic 2010: RT stereotassica cerebrale Lapatinib+ capecitabina Nov 2011 RC Ottobre 2009 IV stadio RT femore dx Zometa Trastuzumab+ Paclitaxel Febbraio 2010 RC Zometa+ trastuzumab Nov 2010 PD SNC LN Osso Marzo 2011 RC PET/TC RM encefalo PET/TC RM encefalo

  16. Novembre 2011

  17. Grazie!

More Related